MabThera/Rituxan

Deal Watch November 2016

We are starting to see more deals covering biosimilars and this month Poland-based Mabion signed a supply and commercialisation agreement with Mylan for a biosimilar of Roche's ... competitors. The patents covering MabThera/Rituxan expired in Europe in

Genentech names Anderson new CEO as Ian Clark retires

Big-selling brands such as breast cancer therapy Herceptin (trastuzumab), Avastin (bevacizumab) for solid tumours and MabThera/Rituxan (rituximab) for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are

Deal Watch October 2016

Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development.

Roche in "unprecedented" launch period for new medicines

Two of Roche's other big sellers - MabThera/Rituxan (rituximab) and Avastin (bevacizumab) - managed to grow slightly despite competition and pricing pressure. ... Avastin is already facing biosimilar competition in some emerging markets and MabThera

AbbVie and Roche's leukaemia drug venetoclax nears EU market

It is also being tested in combination with Roche's $7bn brand MabThera/Rituxan (rituximab), which is widely-used for CLL, as well as Imbruvica which also cleared $1.2bn in

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]